Trials / Completed
CompletedNCT02486874
Clinical Evaluation of PoreSkin
Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
PoreSkin, a human acellular dermal matrix (hADM) manufactured by Faculty of Medicine, Chulalongkorn University, is the first human dermal substitute developed in Thailand. It is a permanent dermal substitute aiming to reduce skin contracture. The objective of this study is to assess the safety and ability in achieving durable and cosmetic coverage of PoreSkin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PoreSkin | a human acellular dermal matrix |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2015-07-01
- Last updated
- 2015-07-01
Source: ClinicalTrials.gov record NCT02486874. Inclusion in this directory is not an endorsement.